ArticleJournal of ovarian research2025
Pretreatment with oral contraceptives benefit POSEIDON group 1 low prognosis patients during GnRH-antagonist protocol: a propensity score-matched retrospective cohort study.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPoor ovarian response (POR) is a challenging condition in assisted reproduction technology. Oral contraceptives (OCs) are commonly used to suppress gonadotropin hormone release in POR patients to synchronize the development of antral follicles before ovarian stimulation. Nevertheless, the question of whether such approach confers advantageous outcomes has elicited inconclusive results in previous studies. Therefore, the objective of this study was to investigate the effect of OCs pretreatment in low prognosis patients stratified by Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) criteria.
methodsThis retrospective cohort study included 2,222 patients undergoing their first IVF or ICSI cycle from January 2012 to April 2022. After propensity score matching, 369 patients were in the OC pretreatment group and 879 in the control group. Patients were divided into four subgroups based on the POSEIDON criteria. Comparisons of ovarian response and clinical outcomes were conducted, and multivariable logistic regression was used to assess the association between OCs pretreatment and live birth, clinical pregnancy, and pregnancy loss rates.
resultsPatients in POSEIDON group 1 who received OCs pretreatment exhibited a significant reduction in the dose and duration of gonadotropin administration, along with an increase in the number of oocytes retrieved, 2 pronuclei, available embryos, and good quality embryos, indicating an improvement in their ovarian response to exogenous gonadotropins. Additionally, the live birth rate (P = 0.030) and clinical pregnancy rate (P = 0.012) were significantly higher in the OCs pretreatment group. Multivariate logistic regression analysis demonstrated a positive association between OCs pretreatment and live birth rate (P = 0.008) and clinical pregnancy rate (P = 0.008). However, in POSEIDON group 2 to group 4, there were no significant differences in ovarian response or clinical outcomes between the OCs pretreatment group and the control group.
conclusionsAdministering OCs as pretreatment prior to ovarian stimulation using gonadotrophin releasing hormone antagonist protocol appears to be a more favorable approach than waiting for natural menses in low prognosis patients belonging to POSEIDON group 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.